University of Minnesota
https://twin-cities.umn.edu/
612-625-5000
Milestone
4.2.e

Advanced clinical evaluation

Completed
High priority

Continue to analyze outcomes from broadly protective vaccine candidates in phase 1 trials and advance promising candidates into phase 2 and phase 3 clinical trials, including in high-risk populations.

Progress Highlights

WHO SAGE 2022 defined “high-risk” groups for developing severe disease resulting in hospitalization or death (such as older adults, pregnant women and women up to 2 weeks postpartum, children, people with a BMI or 40 or higher, and people with comorbidities) and those at increased risk of exposure to or transmission of influenza virus (such as health workers).

See position paper

Several potentially universal, broadly protective, or next-generation influenza vaccine candidates are in phase 2 trials.

See vaccine technology landscape